Ваши амбиции, наш опыт
НОВОСТИ
-
IBA REPORTS FULL YEAR RESULTS FOR 2017
Louvain-La-Neuve, Belgium, March 22, 2018 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its audited consolidated annual results for the 2017 financial year. -
IBA Reports Full Year Results for 2016
Group revenues up 21.6% to EUR 329 million Record REBIT up 25.7% to EUR 37 million, at 11.3% of revenues Proton Therapy and Other Accelerators backlog EUR 336 million -
IBA TRADING UPDATE - THIRD QUARTER 2016
- Group revenue up 19.3%, full year 2016 revenue growth guidance of approximately 20% -
IBA REPORTS HALF YEAR 2016 RESULTS
Total Group H1 revenues of EUR 145.1 million, up 19.9% (H1 2015: EUR 121 million) – on track to meet full-year 2016 revenue growth guidance of above 20% -
IBA Cyclone® 70 at Zevacor Molecular fully...
The cyclotron reached full beam power (700μA) at full energy only 10 months after delivery of the accelerator. The Cyclone® 70 is now fully operational for radioisotope production.
